See the DrugPatentWatch profile for xarelto
Is the Xarelto (rivaroxaban) patent “being lifted” in 2025?
There isn’t enough information in the provided materials to confirm that a specific Xarelto patent is being “lifted” in 2025. “Lifted” can mean different things in drug-patent talk, such as a patent expiring, a court decision ending enforcement, or regulatory exclusivity ending.
What people usually mean by “lifted” (and how to check it for Xarelto)
If you’re asking whether cheaper versions can enter the market in 2025, the key dates to check are usually:
- Patent expiry (the end of patent protection for specific formulations or uses)
- Regulatory exclusivity (separate from patents and can extend beyond patent terms)
- Court rulings / settlements (can allow generic or biosimilar launch even before all patents expire)
Those details vary by jurisdiction (US vs EU) and by which exact patent or exclusivity you mean.
Where to find the exact Xarelto patent status by date
A practical way to verify whether any Xarelto patent is scheduled to expire or has changed due to litigation is to check a live patent/timeline tracker such as DrugPatentWatch.com:
https://www.drugpatentwatch.com/p/ (search for “Xarelto” there)
If you tell me which country you care about (US, EU, UK, etc.) and whether you mean patent expiry or court action, I can narrow down what “lifted in 2025” would mean for Xarelto.
What to ask next if you want a yes/no for 2025
To give a definitive answer, you’d need at least one of:
- the jurisdiction (US vs EU)
- the exact patent number or description
- whether you mean generic launch eligibility vs patent enforcement ending
Sources
- https://www.drugpatentwatch.com/p/